Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study

ÖZMEN V., ÇAKAR B., GÖKMEN E., ÖZDOĞAN M., GÜLER N., URAS C., ...Daha Fazla

EUROPEAN JOURNAL OF BREAST HEALTH, cilt.15, sa.3, ss.183-190, 2019 (Hakemli Dergi) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 3
  • Basım Tarihi: 2019
  • Doi Numarası: 10.5152/ejbh.2019.4761
  • Dergi Adı: EUROPEAN JOURNAL OF BREAST HEALTH
  • Derginin Tarandığı İndeksler: TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.183-190
  • Anahtar Kelimeler: Early breast cancer, genetic profiling, oncotype-Dx, cost, markov model, QUALITY-OF-LIFE, RECURRENCE SCORE, CHEMOTHERAPY, TAMOXIFEN, ASSAY, RISK
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Objective: Breast cancer is a heterogenous disease, and genetic profiling helps to individualize adjuvant treatment. The Oncotype DX is a validated test to predict benefit of adjuvant systemic treatment. The aims of this study are to determine the costs of chemotherapy in government hospitals in Turkey and evaluate the cost-effectiveness of the Oncotype DX from the national insurance perspective.